These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8209101)

  • 21. [Pathophysiology and treatment of renal osteodystrophy].
    Ionova D
    Vutr Boles; 1985; 24(6):23-9. PubMed ID: 3913143
    [No Abstract]   [Full Text] [Related]  

  • 22. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
    Rahamimov R; Silver J
    Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal insufficiency-induced bone loss is associated with an increase in bone size and preservation of strength in rat proximal femur.
    Jokihaara J; Järvinen TL; Jolma P; Kööbi P; Kalliovalkama J; Tuukkanen J; Saha H; Sievänen H; Kannus P; Pörsti I
    Bone; 2006 Aug; 39(2):353-60. PubMed ID: 16584934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal osteodystrophy, phosphate homeostasis, and vascular calcification.
    Hruska KA; Saab G; Mathew S; Lund R
    Semin Dial; 2007; 20(4):309-15. PubMed ID: 17635820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of bone scintigraphy, densitometry and radiography in secondary hyperparathyroidism in patients with chronic renal failure].
    Kosowicz J; Bolko P; Swiderski A
    Pol Arch Med Wewn; 2003 Feb; 109(2):125-35. PubMed ID: 12879775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Studies on the pathogenesis and pathophysiology of renal osteodystrophy. II. Bone histology of chronic renal failure patients at the time of starting hemodialysis].
    Sato T
    Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1145-58. PubMed ID: 7815747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure.
    Malluche HH; Faugère MC; Ritz E; Caillens G; Wildberger D
    Miner Electrolyte Metab; 1986; 12(2):113-8. PubMed ID: 3960014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-dependent effects of strontium on bone of chronic renal failure rats.
    Schrooten I; Behets GJ; Cabrera WE; Vercauteren SR; Lamberts LV; Verberckmoes SC; Bervoets AJ; Dams G; Goodman WG; De Broe ME; D'Haese PC
    Kidney Int; 2003 Mar; 63(3):927-35. PubMed ID: 12631073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of renal osteodystrophy: roles of phosphate and skeletal resistance to PTH.
    Ritz E; Malluche HH; Krempien B; Tschope W; Massry SG
    Adv Exp Med Biol; 1978; 103():423-36. PubMed ID: 362849
    [No Abstract]   [Full Text] [Related]  

  • 30. [Vitamin D metabolism and chronic kidney insufficiency].
    Schaefer K; von Herrath D; Kraft D
    Dtsch Med Wochenschr; 1973 Jul; 98(27):1338-44. PubMed ID: 4351844
    [No Abstract]   [Full Text] [Related]  

  • 31. Special aspects of renal osteodystrophy in children.
    Salusky IB; Kuizon BG; Jüppner H
    Semin Nephrol; 2004 Jan; 24(1):69-77. PubMed ID: 14730512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parathyroid hormone (PTH)/PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency.
    Turner G; Coureau C; Rabin MR; Escoubet B; Hruby M; Walrant O; Silve C
    Endocrinology; 1995 Sep; 136(9):3751-8. PubMed ID: 7649081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyroid function in chronic vitamin D deficiency in man: a model for comparison with chronic renal failure.
    Stanbury SW; Lumb GA
    Calcif Tissue Res; 1976 Aug; 21 Suppl():185-201. PubMed ID: 953806
    [No Abstract]   [Full Text] [Related]  

  • 34. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
    Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
    Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
    Hirata M; Katsumata K; Masaki T; Koike N; Endo K; Tsunemi K; Ohkawa H; Kurokawa K; Fukagawa M
    Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 38. Minor influence of parathyroid hormone on fractional tubular reabsorption of phosphate in chronic renal failure.
    Christensen MS; Brochner-Mortensen J; Tougaard L; Sorensen E; Rodbro P
    Adv Exp Med Biol; 1977; 81():131-9. PubMed ID: 899922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parathyroid dysfunction end stage renal disease.
    DiTella PJ; Lang GR
    Otolaryngol Clin North Am; 1980 Feb; 13(1):193-201. PubMed ID: 7367004
    [No Abstract]   [Full Text] [Related]  

  • 40. [Importance of estrogen insufficiency time in the efficacy of the bone response to hormonal therapy in experimental chronic renal insufficiency].
    Rodríguez Rodríguez A; Naves Díaz M; Díaz Corte C; González Carcedo A; Fernández Coto T; Cannata Andía JB
    Nefrologia; 2003; 23 Suppl 2():84-90. PubMed ID: 12778861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.